These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 23194076

  • 21. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T, Ladrón de Guevara A, Codner E, Preisler J, Crisosto N, Echiburú B, Maliqueo M, Sánchez F, Perez-Bravo F, Cassorla F.
    Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
    [Abstract] [Full Text] [Related]

  • 22. Circulating anti-Müllerian hormone levels in relation to nutritional status and selected adipokines levels in polycystic ovary syndrome.
    Olszanecka-Glinianowicz M, Madej P, Owczarek A, Chudek J, Skałba P.
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):98-104. PubMed ID: 25440474
    [Abstract] [Full Text] [Related]

  • 23. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight-obese adolescent patients with polycystic ovary syndrome.
    Cengiz H, Ekin M, Dagdeviren H, Yildiz Ş, Kaya C, Kanawati A.
    Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():46-50. PubMed ID: 25036408
    [Abstract] [Full Text] [Related]

  • 24. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL.
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
    [Abstract] [Full Text] [Related]

  • 25. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.
    Sova H, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, Tinkanen H, Puukka K, Bloigu R, Piltonen T, Tapanainen JS, Morin-Papunen L.
    Gynecol Endocrinol; 2019 Jul; 35(7):595-600. PubMed ID: 30668196
    [Abstract] [Full Text] [Related]

  • 26. Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
    Koiou E, Tziomalos K, Katsikis I, Kandaraki EA, Kalaitzakis E, Delkos D, Vosnakis C, Panidis D.
    Gynecol Endocrinol; 2012 Jan; 28(1):20-4. PubMed ID: 21756081
    [Abstract] [Full Text] [Related]

  • 27. Anti-Müllerian hormone gene polymorphism is associated with androgen levels in Chinese polycystic ovary syndrome patients with insulin resistance.
    Zheng MX, Li Y, Hu R, Wang FM, Zhang XM, Guan B.
    J Assist Reprod Genet; 2016 Feb; 33(2):199-205. PubMed ID: 26732661
    [Abstract] [Full Text] [Related]

  • 28. Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study.
    Mehrabani HH, Salehpour S, Amiri Z, Farahani SJ, Meyer BJ, Tahbaz F.
    J Am Coll Nutr; 2012 Apr; 31(2):117-25. PubMed ID: 22855917
    [Abstract] [Full Text] [Related]

  • 29. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.
    Pierre A, Peigné M, Grynberg M, Arouche N, Taieb J, Hesters L, Gonzalès J, Picard JY, Dewailly D, Fanchin R, Catteau-Jonard S, di Clemente N.
    Hum Reprod; 2013 Mar; 28(3):762-9. PubMed ID: 23321213
    [Abstract] [Full Text] [Related]

  • 30. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
    Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ.
    Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152
    [Abstract] [Full Text] [Related]

  • 31. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO.
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [Abstract] [Full Text] [Related]

  • 32. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [Abstract] [Full Text] [Related]

  • 33. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM, Fenkci V, Oztekin O, Rota S, Karagenc N.
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [Abstract] [Full Text] [Related]

  • 34. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F, Zamani MM, Heshmat R, Moini nia F.
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [Abstract] [Full Text] [Related]

  • 35. The use of anti-mullerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome.
    Moran LJ, Noakes M, Clifton PM, Norman RJ.
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3796-802. PubMed ID: 17652213
    [Abstract] [Full Text] [Related]

  • 36. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
    Katsikis I, Karkanaki A, Misichronis G, Delkos D, Kandaraki EA, Panidis D.
    Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
    [Abstract] [Full Text] [Related]

  • 37. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome.
    Enli Y, Fenkci SM, Fenkci V, Oztekin O.
    Gynecol Endocrinol; 2013 Dec; 29(12):1036-9. PubMed ID: 23961784
    [Abstract] [Full Text] [Related]

  • 38. The effect of weight loss program on serum anti-Müllerian hormone level in obese and overweight infertile women with polycystic ovary syndrome.
    Moini A, Arabipoor A, Hemat M, Ahmadi J, Salman-Yazdi R, Zolfaghari Z.
    Gynecol Endocrinol; 2019 Feb; 35(2):119-123. PubMed ID: 30580636
    [Abstract] [Full Text] [Related]

  • 39. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
    Sahmay S, Atakul N, Aydogan B, Aydin Y, Imamoglu M, Seyisoglu H.
    Acta Obstet Gynecol Scand; 2013 Dec; 92(12):1369-74. PubMed ID: 23980726
    [Abstract] [Full Text] [Related]

  • 40. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D.
    Hormones (Athens); 2013 Dec; 12(4):559-66. PubMed ID: 24457404
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.